Bausch & Lomb Meets Growth Goals and Increases R&D, but Bausch Health Uncertainty Still Weighs on Shares

Narrow-moat Bausch & Lomb had a decent quarter with 6% constant currency sales growth driven by demand for Lumify redness relieving drops, increased share of daily lenses, and higher demand for lens solution, as consumers traveled and took part in more outdoor activities than in the last year. We just relaunched coverage of the company on August 1 with a $25 fair value estimate, and we are keeping this valuation intact while slightly reducing our full-year expectations to account for the negative effects of inflation and currency changes.